$13.92
0.01[0.07%]
Last update: 9:30AM Get Real Time Here
TG Therapeutics
(NASDAQ:TGTX)TG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, Predictions
TG Therapeutics Inc has a consensus price target of $20.36, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., JP Morgan, and Ladenburg Thalmann on April 18, 2024. With an average price target of $36.33 between HC Wainwright & Co., JP Morgan, and Ladenburg Thalmann, there's an implied 167.16% upside for TG Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Ladenburg Thalmann
Goldman Sachs
B. Riley Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for TG Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | 230.88% | HC Wainwright & Co. | Edward White | → $45 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | 83.82% | JP Morgan | Eric Joseph | → $25 | Reiterates | Overweight → Overweight | Get Alert |
| 04/18/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | 186.76% | Ladenburg Thalmann | Matthew Kaplan | → $39 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | 230.88% | HC Wainwright & Co. | Edward White | → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | -4.41% | Goldman Sachs | Corinne Jenkins | $12 → $13 | Maintains | Neutral | Get Alert |
| 02/28/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | 230.88% | HC Wainwright & Co. | Edward White | → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/05/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | 113.24% | B. Riley Securities | Mayank Mamtani | $24 → $29 | Maintains | Buy | Get Alert |
| 01/11/2024 | TGTX | Buy Now | TG Therapeutics | $13.60 | 230.88% | HC Wainwright & Co. | Edward White | $41 → $45 | Maintains | Buy | Get Alert |
| 11/01/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | — | Jefferies | Matthew Andrews | — | Maintains | Buy | Get Alert |
| 11/01/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 69.12% | JP Morgan | Eric Joseph | $22 → $23 | Maintains | Overweight | Get Alert |
| 10/20/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 76.47% | B. Riley Securities | Mayank Mamtani | $32 → $24 | Maintains | Buy | Get Alert |
| 09/18/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 201.47% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 61.76% | JP Morgan | Eric Joseph | $34 → $22 | Maintains | Overweight | Get Alert |
| 08/03/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | -11.76% | Goldman Sachs | Corinne Jenkins | $16 → $12 | Maintains | Neutral | Get Alert |
| 08/02/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 135.29% | B. Riley Securities | Mayank Mamtani | $42 → $32 | Maintains | Buy | Get Alert |
| 08/02/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | -11.76% | Goldman Sachs | Corinne Jenkins | $16 → $12 | Upgrade | Sell → Neutral | Get Alert |
| 08/01/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 135.29% | B. Riley Securities | Mayank Mamtani | $42 → $32 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 201.47% | HC Wainwright & Co. | Edward White | $34 → $41 | Maintains | Buy | Get Alert |
| 07/25/2023 | TGTX | Buy Now | TG Therapeutics | $13.60 | 17.65% | Goldman Sachs | Corinne Jenkins | $10 → $16 | Maintains | Sell | Get Alert |
FAQ
What is the target price for TG Therapeutics (TGTX)?
The latest price target for TG Therapeutics (NASDAQ: TGTX) was reported by HC Wainwright & Co. on April 18, 2024. The analyst firm set a price target for $45.00 expecting TGTX to rise to within 12 months (a possible 223.28% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TG Therapeutics (TGTX)?
The latest analyst rating for TG Therapeutics (NASDAQ: TGTX) was provided by HC Wainwright & Co., and TG Therapeutics reiterated their buy rating.
When was the last upgrade for TG Therapeutics (TGTX)?
The last upgrade for TG Therapeutics Inc happened on August 2, 2023 when Goldman Sachs raised their price target to $12. Goldman Sachs previously had a sell for TG Therapeutics Inc.
When was the last downgrade for TG Therapeutics (TGTX)?
The last downgrade for TG Therapeutics Inc happened on November 15, 2021 when Goldman Sachs changed their price target from $33 to $26 for TG Therapeutics Inc.
When is the next analyst rating going to be posted or updated for TG Therapeutics (TGTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TG Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TG Therapeutics was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating TG Therapeutics (TGTX) correct?
While ratings are subjective and will change, the latest TG Therapeutics (TGTX) rating was a reiterated with a price target of $0.00 to $45.00. The current price TG Therapeutics (TGTX) is trading at is $13.92, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.